Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.40 |
| ▸ | EIF4EBP1 | Q13541 | 9/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488927 | 0.89 | MRGPRX4 (0.44) | DCTPP1EIF4EBP1MRGPRX4 | |
| SCHEMBL6490645 | 0.85 | PTGDR (0.44) | RXRARXRBDCTPP1EIF4EBP1PPARG | |
| SCHEMBL6489563 | 0.83 | SMN1; SMN2 (0.52) | RXRARXRBDCTPP1PPARG | |
| SCHEMBL6496733 | 0.81 | ALOX5AP (0.47) | RXRARXRBDCTPP1PPARGMRGPRX4 | |
| SCHEMBL6487982 | 0.79 | DCTPP1 (0.41) | RXRARXRBDCTPP1EIF4EBP1PPARG | |
| SCHEMBL6488966 | 0.79 | RXRA (0.41) | RXRARXRBDCTPP1EIF4EBP1PPARG | |
| SCHEMBL6492692 | 0.79 | USP2 (0.45) | PPARG | |
| SCHEMBL6490617 | 0.78 | DCTPP1 (0.43) | RXRARXRBDCTPP1MRGPRX4 | |
| SCHEMBL6488962 | 0.77 | MRGPRX4 (0.41) | DCTPP1MRGPRX4 | |
| SCHEMBL6491005 | 0.77 | BCL2 (0.47) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | RXRA 2329/4885RXRB 2252/4885DCTPP1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.